161 related articles for article (PubMed ID: 20427506)
1. Repair of aberrant splicing in growth hormone receptor by antisense oligonucleotides targeting the splice sites of a pseudoexon.
David A; Srirangalingam U; Metherell LA; Khoo B; Clark AJ
J Clin Endocrinol Metab; 2010 Jul; 95(7):3542-6. PubMed ID: 20427506
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterisation of a novel GHR defect disrupting the polypyrimidine tract and resulting in GH insensitivity.
David A; Miraki-Moud F; Shaw NJ; Savage MO; Clark AJ; Metherell LA
Eur J Endocrinol; 2010 Jan; 162(1):37-42. PubMed ID: 19812236
[TBL] [Abstract][Full Text] [Related]
3. Dual Fluorescence Splicing Reporter Minigene Identifies an Antisense Oligonucleotide to Skip Exon v8 of the
Fukushima S; Farea M; Maeta K; Rani AQM; Fujioka K; Nishio H; Matsuo M
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33266296
[TBL] [Abstract][Full Text] [Related]
4. Growth Hormone Receptor (GHR) 6Ω Pseudoexon Activation: a Novel Cause of Severe Growth Hormone Insensitivity.
Cottrell E; Maharaj A; Williams J; Chatterjee S; Cirillo G; Miraglia Del Giudice E; Festa A; Palumbo S; Capalbo D; Salerno M; Pignata C; Savage MO; Schilbach K; Bidlingmaier M; Hwa V; Metherell LA; Grandone A; Storr HL
J Clin Endocrinol Metab; 2021 Jul; ():. PubMed ID: 34453441
[TBL] [Abstract][Full Text] [Related]
5. Growth Hormone Receptor (Ghr) 6ω Pseudoexon Activation: A Novel Cause Of Severe Growth Hormone Insensitivity (Ghi).
Cottrell E; Maharaj A; Williams J; Chatterjee S; Cirillo G; Miraglia Del Giudice E; Festa A; Palumbo S; Capalbo D; Salerno M; Pignata C; Savage MO; Schilbach K; Bidlingmaier M; Hwa V; Metherell LA; Grandone A; Storr HL
J Clin Endocrinol Metab; 2021 Jul; 107(1):e401-16. PubMed ID: 34318893
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the regulatory effects of synthesized antisense oligonucleotides on androgen receptor (AR) exon 3 splicing in prostate cancer cells.
Wang L; Gong S; Zhang X; Azhar Z; Chen J
Gene; 2023 May; 866():147330. PubMed ID: 36871670
[TBL] [Abstract][Full Text] [Related]
7. A short isoform of the human growth hormone receptor functions as a dominant negative inhibitor of the full-length receptor and generates large amounts of binding protein.
Ross RJ; Esposito N; Shen XY; Von Laue S; Chew SL; Dobson PR; Postel-Vinay MC; Finidori J
Mol Endocrinol; 1997 Mar; 11(3):265-73. PubMed ID: 9058373
[TBL] [Abstract][Full Text] [Related]
8. GHR gene transcript heterogeneity may explain phenotypic variability in GHR pseudoexon (6Ψ) patients.
Chatterjee S; Cottrell E; Rose SJ; Mushtaq T; Maharaj AV; Williams J; Savage MO; Metherell LA; Storr H
Endocr Connect; 2020 Feb; 9(3):211-22. PubMed ID: 32061156
[TBL] [Abstract][Full Text] [Related]
9. In vitro correction of a pseudoexon-generating deep intronic mutation in LGMD2A by antisense oligonucleotides and modified small nuclear RNAs.
Blázquez L; Aiastui A; Goicoechea M; Martins de Araujo M; Avril A; Beley C; García L; Valcárcel J; Fortes P; López de Munain A
Hum Mutat; 2013 Oct; 34(10):1387-95. PubMed ID: 23864287
[TBL] [Abstract][Full Text] [Related]
10. Characterization of dominant-negative growth hormone receptor variants reveals a potential therapeutic target for short stature.
Andrews A; Cottrell E; Maharaj A; Ladha T; Williams J; Schilbach K; Kaisinger LR; Perry JRB; Metherell LA; McCormick PJ; Storr HL
Eur J Endocrinol; 2023 Apr; 188(4):353-365. PubMed ID: 36943306
[TBL] [Abstract][Full Text] [Related]
11. An intronic growth hormone receptor mutation causing activation of a pseudoexon is associated with a broad spectrum of growth hormone insensitivity phenotypes.
David A; Camacho-Hübner C; Bhangoo A; Rose SJ; Miraki-Moud F; Akker SA; Butler GE; Ten S; Clayton PE; Clark AJ; Savage MO; Metherell LA
J Clin Endocrinol Metab; 2007 Feb; 92(2):655-9. PubMed ID: 17148568
[TBL] [Abstract][Full Text] [Related]
12. Antisense-mediated exon inclusion.
Hua Y; Krainer AR
Methods Mol Biol; 2012; 867():307-23. PubMed ID: 22454070
[TBL] [Abstract][Full Text] [Related]
13. Hybridization-mediated off-target effects of splice-switching antisense oligonucleotides.
Scharner J; Ma WK; Zhang Q; Lin KT; Rigo F; Bennett CF; Krainer AR
Nucleic Acids Res; 2020 Jan; 48(2):802-816. PubMed ID: 31802121
[TBL] [Abstract][Full Text] [Related]
14. Pseudoexon activation as a novel mechanism for disease resulting in atypical growth-hormone insensitivity.
Metherell LA; Akker SA; Munroe PB; Rose SJ; Caulfield M; Savage MO; Chew SL; Clark AJ
Am J Hum Genet; 2001 Sep; 69(3):641-6. PubMed ID: 11468686
[TBL] [Abstract][Full Text] [Related]
15. Successful skipping of abnormal pseudoexon by antisense oligonucleotides in vitro for a patient with beta-propeller protein-associated neurodegeneration.
Yamada M; Maeta K; Suzuki H; Kurosawa R; Takenouchi T; Awaya T; Ajiro M; Takeuchi A; Nishio H; Hagiwara M; Miya F; Matsuo M; Kosaki K
Sci Rep; 2024 Mar; 14(1):6506. PubMed ID: 38499569
[TBL] [Abstract][Full Text] [Related]
16. Antisense Oligonucleotide Rescue of Deep-Intronic Variants Activating Pseudoexons in the 6-Pyruvoyl-Tetrahydropterin Synthase Gene.
Martínez-Pizarro A; Leal F; Holm LL; Doktor TK; Petersen USS; Bueno M; Thöny B; Pérez B; Andresen BS; Desviat LR
Nucleic Acid Ther; 2022 Oct; 32(5):378-390. PubMed ID: 35833796
[TBL] [Abstract][Full Text] [Related]
17. RNA Secondary Structure-Based Design of Antisense Peptide Nucleic Acids for Modulating Disease-Associated Aberrant Tau Pre-mRNA Alternative Splicing.
Ong AAL; Tan J; Bhadra M; Dezanet C; Patil KM; Chong MS; Kierzek R; Decout JL; Roca X; Chen G
Molecules; 2019 Aug; 24(16):. PubMed ID: 31434312
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biochemical consequences of an intragenic growth hormone receptor (GHR) deletion in a large Chinese pedigree.
Klammt J; Shen S; Kiess W; Kratzsch J; Stobbe H; Vogel M; Luo F; Pfäffle R
Clin Endocrinol (Oxf); 2015 Mar; 82(3):453-61. PubMed ID: 25196842
[TBL] [Abstract][Full Text] [Related]
19. Splice-Switching Antisense Oligonucleotides Correct Phenylalanine Hydroxylase Exon 11 Skipping Defects and Rescue Enzyme Activity in Phenylketonuria.
Martínez-Pizarro A; Álvarez M; Dembic M; Lindegaard CA; Castro M; Richard E; Andresen BS; Desviat LR
Nucleic Acid Ther; 2024; 34(3):134-142. PubMed ID: 38591802
[TBL] [Abstract][Full Text] [Related]
20. RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus.
Liang XH; Sun H; Nichols JG; Crooke ST
Mol Ther; 2017 Sep; 25(9):2075-2092. PubMed ID: 28663102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
